COVID-19 - Updates Archives

September 22, 2022

ASH 2021: Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

Dr. David Cucchi and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021). Since the meeting, a more detailed report has been published here.

September 12, 2022

New Bivalent COVID-19 Booster Guidance Released by the CDC

As a recap, if you have received either of the mRNA vaccines, namely Pfizer and Moderna, the “primary series” of COVID-19 consists of three full-strength shots for CLL/SLL patients, NOT two (as is the case for those with a healthy immune system).

August 26, 2022

Dr. Brian Koffman Shares His Experience Receiving Evusheld with ASPR to Increase Awareness and Access Across Healthcare Practices in the United States

CLL Society believes that every immunocompromised individual, including those with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), regardless of treatment status, should experience easy access to the life-saving pre-exposure prophylaxis therapy or PreP, Evusheld.

August 22, 2022

What Those with CLL/SLL Need to Know About the Latest CDC Guidance for Minimizing the Impact of COVID-19

In the new COVID-19 guidelines released on August 11th, the US Centers for Disease Control and Prevention (CDC) made a change in their recommended infection control measures that are geared more towards increasing the focus on individuals understanding their own risk level for developing severe COVID-19 disease, making a personal decision

July 13, 2022

The FDA Authorizes Pharmacists to Prescribe Paxlovid to Eligible Patients Who Test Positive for COVID-19

This is part of a concerted effort to make sure all those with a high risk for progression to a severe case of COVID-19 have quick and easy access to appropriate therapy. In addition, since Paxlovid therapy should be started within five days of the infection, this change should

July 13, 2022

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone

July 1, 2022

FDA Authorizes Revisions to Evusheld Dosing

On June 29, 2022, the FDA announced its long-awaited guidelines on the timing of a second Evusheld dose.

April 21, 2022

Answering the Most Common Questions About COVID-19 Booster Doses and Evusheld for Those with CLL/SLL

CLL Society has been receiving multiple questions surrounding Evusheld and the newly recommended second booster dose (fifth dose in total) for all individuals who are immunocompromised. These new recommendations are applicable to everyone with CLL/SLL.

April 21, 2022

COVID-19 Vaccine Refusal and Fair Allocation of Scarce Medical Resources: Moving CLL/SLL and Other Immunocompromised Patients to the Top Tier

In a pandemic with scarce resources, governments, medical institutions, and healthcare providers have had to make decisions and/or policies about allocating potentially lifesaving therapies among the many outpatients who might benefit from them.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

COVID-19 – Updates

ASH 2021: Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

New Bivalent COVID-19 Booster Guidance Released by the CDC

Dr. Brian Koffman Shares His Experience Receiving Evusheld with ASPR to Increase Awareness and Access Across Healthcare Practices in the United States

What Those with CLL/SLL Need to Know About the Latest CDC Guidance for Minimizing the Impact of COVID-19

The FDA Authorizes Pharmacists to Prescribe Paxlovid to Eligible Patients Who Test Positive for COVID-19

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

FDA Authorizes Revisions to Evusheld Dosing

Answering the Most Common Questions About COVID-19 Booster Doses and Evusheld for Those with CLL/SLL

COVID-19 Vaccine Refusal and Fair Allocation of Scarce Medical Resources: Moving CLL/SLL and Other Immunocompromised Patients to the Top Tier

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT